THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...

As of January 15, 2025, third line (3L) data showed median overall survival (OS) of 16.9 months for the 22 NSCLC patients who received at least one dose of THIO (the intent-to-treat population ...

The trial evaluates THIO, a telomere-targeting agent, in combination with Regeneron (NASDAQ:REGN)'s cemiplimab, an immune checkpoint inhibitor, in patients who have not responded to at least two ...

In summary, MAIA Biotechnology’s recent updates regarding its Phase 2 THIO-101 trial demonstrate the company’s commitment to communicating significant developments in its oncology research ...

Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. Azitra is a ...

CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company with a market capitalization of $49.4 million, has announced updated data from its Phase 2 clinical ...

A plan for the US Food and Drug Administration to propose banning formaldehyde and certain formaldehyde-releasing chemicals ...

Almost all workers are being pulled out of the US Agency for International Development (USAID), the Trump administration has said. The move all but ends a six-decade mission to shore up American ...

I review privacy tools like hardware security keys, password managers, private messaging apps and ad-blocking software. I also report on online scams and offer advice to families and individuals ...

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today ...